SCHEDULE 13G/A: AP11 Limited and Ascletis Pharma Inc. Disclose 4.9% Passive Stake in Sagimet Biosciences

AP11 Limited and Ascletis Pharma Inc. have filed an amendment to their Schedule 13G, reporting a passive beneficial ownership of 4.9% in Sagimet Biosciences Inc.'s Series A common stock.

Summary

• AP11 Limited and Ascletis Pharma Inc. filed an Amendment No. 1 to their Schedule 13G.
• The reporting persons collectively beneficially own 1,504,642 shares of Sagimet Biosciences Inc.'s Series A common stock.
• This ownership represents 4.9% of the Series A common stock outstanding.
• The percentage is calculated based on 30,674,855 shares of Series A common stock outstanding as of June 10, 2025, as reported by Sagimet Biosciences Inc. in a Form 8-K.
• Both AP11 Limited and Ascletis Pharma Inc. hold sole voting and sole dispositive power over the 1,504,642 shares.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of passive beneficial ownership and does not contain information that inherently indicates a positive or negative outlook for the company's performance or operations.

Industry Context

This filing is a routine disclosure of passive beneficial ownership, common in the biotechnology and pharmaceutical sectors where institutional investors or strategic partners may hold stakes.

Related Party Transactions

• AP11 Limited and Ascletis Pharma Inc. are filing jointly as reporting persons, holding identical beneficial ownership stakes and sharing the same principal business office address, suggesting a control relationship between the two entities.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant passive investor's stake, which is now below the 5% threshold for ongoing Schedule 13G reporting.

Key Dates

Keywords

Sagimet Biosciences, AP11 Limited, Ascletis Pharma, Schedule 13G, Beneficial Ownership, Series A common stock, Passive Investment